Results 61 to 70 of about 33,791,512 (292)
This review summarizes the pathogenic role of mitochondria in diseases and highlights mitochondrial transfer and transplantation as emerging therapeutic strategies. It systematically discusses how nanomaterials are engineered to facilitate these processes, and critically examines the current challenges and future perspectives for their clinical ...
Yuanyuan Su +9 more
wiley +1 more source
Glucagon-like peptide-1 agonists are effective weight loss treatments, yet few data are available regarding their use in patients with durable left ventricular assist devices.
Michele Edwards, MSN, APRN +9 more
doaj +1 more source
Direct visualization of glucagon‐like peptide‐1 secretion by fluorescent fusion proteins
Live‐cell imaging with fluorescent proteins (FPs) is a powerful tool for investigating the exocytosis processes of hormones. However, the secretion process of glucagon‐like peptide‐1 (GLP‐1) has not been visualized by FPs, which might be because tagging ...
Atsushi Tsuzuki +9 more
doaj +1 more source
Perioperative Practice Patterns of Anaesthesiologists Surrounding Glucagon-Like Peptide-1 (GLP-1) Agonist Medications [PDF]
Objective: Aspiration of gastric contents during induction of anaesthesia is a rare but well-recognized complication with high morbidity and mortality risk.
Sabrina H. Han +8 more
core +1 more source
Researchers developed an engineered probiotic encapsulated in an inulin hydrogel, enabling ultrasound‐triggered intestinal delivery of IL‐22. In MASH model mice, this system remodeled gut microbiota, strengthened the intestinal barrier and reduced portal LPS and hepatic IL‐6.
Chunya Ji +11 more
wiley +1 more source
Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism [PDF]
PURPOSE OF REVIEW: Glucagon-like peptide-1 (GLP-1) is the best known incretin hormone able to potentiate glucose-induced insulin secretion. Moreover, GLP-1 is currently under intensive investigation as a potential crucial mediator of beneficial metabolic effects after bariatric surgery, because of its eating inhibitory, antiobesity, and antidiabetes ...
Thomas A. Lutz, Elena Osto
openaire +3 more sources
Neuropathic pain represents a significant clinical challenge due to its complex etiology and limited treatment options. Traditional pharmacological approaches, particularly opioid therapy, are associated with significant side effects and risk of abuse ...
Hulya Karatas
doaj +1 more source
Glucagon-like peptide-1 receptor is an important regulator of appetite and glucose homeostasis. Here the authors describe super-resolution microscopy and in vivo imaging compatible fluorescent probes, which reveal endogenous glucagon-like peptide-1 ...
Julia Ast +25 more
doaj +1 more source
Are we waiting too long for the cardiovascular outcome trials with the glucagon-like peptide-1 receptor agonists? [PDF]
Several new medicines are in development for the treatment of type 2 diabetes, and cardiovascular outcome trials are the gold standard for these medicines.
Doggrell, Sheila
core +1 more source
This study identifies GAP2, a bioactive polysaccharide fraction derived from Ganoderma applanatum, as a postbiotic inducer that repairs intestinal barrier damage in a gut microbiota‐dependent manner. GAP2 enriches Phocaeicola vulgatus, which degrades GAP2 and promotes tridecylic acid production, triggering Rho/CDC42 signaling and tight‐junction ...
Chuan Zhang +10 more
wiley +1 more source

